Stock Track | Senseonics Soars 11.52% After-Hours on Eversense 365 Launch Success and Strong 2025 Outlook

Stock Track

Jan 09, 2025

Shares of Senseonics Holdings, Inc. (SENS) surged 11.52% in after-hours trading on Wednesday, following the company's announcement of operational and financial updates, including the successful launch of its Eversense 365 continuous glucose monitoring (CGM) system and a positive outlook for 2025.

Senseonics reported preliminary unaudited fourth-quarter revenue of approximately $8.3 million and full-year 2024 revenue of around $22.5 million. The company highlighted several key achievements in 2024, including receiving FDA approval for and launching the Eversense 365 CGM system in collaboration with its commercial partner, Ascensia.

The launch of Eversense 365, which can monitor glucose levels for up to 365 days with a single implantable sensor, has been met with strong early interest. Senseonics noted a doubling of direct-to-consumer leads in Q4 compared to Q3, a record high of approximately 600 new patient shipments in December, a 49% increase in patients switching from competitive CGM systems, and a 118% surge in physician referrals since the launch.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1125619642"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125619642\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125619642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 07:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125619642","market":"us","top_or_hot":-1,"title":"Stock Track | Senseonics Soars 11.52% After-Hours on Eversense 365 Launch Success and Strong 2025 Outlook","media":"Stock Track","content":"<p>Shares of Senseonics Holdings, Inc. (SENS) surged 11.52% in after-hours trading on Wednesday, following the company's announcement of operational and financial updates, including the successful launch of its Eversense 365 continuous glucose monitoring (CGM) system and a positive outlook for 2025.</p>\n\n<p>Senseonics reported preliminary unaudited fourth-quarter revenue of approximately $8.3 million and full-year 2024 revenue of around $22.5 million. The company highlighted several key achievements in 2024, including receiving FDA approval for and launching the Eversense 365 CGM system in collaboration with its commercial partner, Ascensia.</p>\n\n<p>The launch of Eversense 365, which can monitor glucose levels for up to 365 days with a single implantable sensor, has been met with strong early interest. Senseonics noted a doubling of direct-to-consumer leads in Q4 compared to Q3, a record high of approximately 600 new patient shipments in December, a 49% increase in patients switching from competitive CGM systems, and a 118% surge in physician referrals since the launch.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Senseonics Soars 11.52% After-Hours on Eversense 365 Launch Success and Strong 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Senseonics Soars 11.52% After-Hours on Eversense 365 Launch Success and Strong 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-09 07:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Senseonics Holdings, Inc. (SENS) surged 11.52% in after-hours trading on Wednesday, following the company's announcement of operational and financial updates, including the successful launch of its Eversense 365 continuous glucose monitoring (CGM) system and a positive outlook for 2025.</p>\n\n<p>Senseonics reported preliminary unaudited fourth-quarter revenue of approximately $8.3 million and full-year 2024 revenue of around $22.5 million. The company highlighted several key achievements in 2024, including receiving FDA approval for and launching the Eversense 365 CGM system in collaboration with its commercial partner, Ascensia.</p>\n\n<p>The launch of Eversense 365, which can monitor glucose levels for up to 365 days with a single implantable sensor, has been met with strong early interest. Senseonics noted a doubling of direct-to-consumer leads in Q4 compared to Q3, a record high of approximately 600 new patient shipments in December, a 49% increase in patients switching from competitive CGM systems, and a 118% surge in physician referrals since the launch.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SENS","symbol_name":"Senseonics Holdings,Inc.","start_time":0,"source_url":"","article_id":"1125619642","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125619642","pubTimestamp":1736378217,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Senseonics Holdings, Inc.  surged 11.52% in after-hours trading on Wednesday, following the company's announcement of operational and financial updates, including the successful launch of its Eversense 365 continuous glucose monitoring  system and a positive outlook for 2025.Senseonics reported preliminary unaudited fourth-quarter revenue of approximately $8.3 million and full-year 2024 revenue of around $22.5 million. The company highlighted several key achievements in 2024, including","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SENS":"Senseonics Holdings,Inc."},"translate_title":"Eversense 365发布成功且2025年前景强劲，股票赛道Senseonics盘后飙升11.52%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SENS":1},"content_text":"Shares of Senseonics Holdings, Inc. (SENS) surged 11.52% in after-hours trading on Wednesday, following the company's announcement of operational and financial updates, including the successful launch of its Eversense 365 continuous glucose monitoring (CGM) system and a positive outlook for 2025.\nSenseonics reported preliminary unaudited fourth-quarter revenue of approximately $8.3 million and full-year 2024 revenue of around $22.5 million. The company highlighted several key achievements in 2024, including receiving FDA approval for and launching the Eversense 365 CGM system in collaboration with its commercial partner, Ascensia.\nThe launch of Eversense 365, which can monitor glucose levels for up to 365 days with a single implantable sensor, has been met with strong early interest. Senseonics noted a doubling of direct-to-consumer leads in Q4 compared to Q3, a record high of approximately 600 new patient shipments in December, a 49% increase in patients switching from competitive CGM systems, and a 118% surge in physician referrals since the launch.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}